BRIEF-BiomX Announces Discontinuation Of Phase 2b Bx004 Trial Following Internal Review

Reuters12-08

Dec 8 (Reuters) - Biomx Inc PHGE.A:

BIOMX ANNOUNCES DISCONTINUATION OF PHASE 2B BX004 TRIAL FOLLOWING INTERNAL REVIEW
BIOMX INC - PLANS COST-CUTTING MEASURES INCLUDING WORKFORCE REDUCTION
BIOMX INC - DECISION FOLLOWS SAFETY REVIEW BY INDEPENDENT DMC
BIOMX INC - SEES POTENTIAL IN BX011 FOR S. AUREUS INFECTIONS

Source text: ID:nGNX8KfLKK

Further company coverage: PHGE.A

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589358837?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589358837","market":"nz","top_or_hot":-1,"title":"BRIEF-BiomX Announces Discontinuation Of Phase 2b Bx004 Trial Following Internal Review","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-BiomX Announces Discontinuation Of Phase 2b Bx004 Trial Following Internal Review</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Biomx Inc <span>PHGE.A</span>:</p><ul><li><p>BIOMX ANNOUNCES DISCONTINUATION OF PHASE 2B BX004 TRIAL FOLLOWING INTERNAL REVIEW</p></li><li><p>BIOMX INC - PLANS COST-CUTTING MEASURES INCLUDING WORKFORCE REDUCTION</p></li><li><p>BIOMX INC - DECISION FOLLOWS SAFETY REVIEW BY INDEPENDENT DMC</p></li><li><p>BIOMX INC - SEES POTENTIAL IN BX011 FOR S. AUREUS INFECTIONS</p></li></ul><p>Source text: <span>ID:nGNX8KfLKK</span></p><p>Further company coverage: <span>PHGE.A</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-BiomX Announces Discontinuation Of Phase 2b Bx004 Trial Following Internal Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-BiomX Announces Discontinuation Of Phase 2b Bx004 Trial Following Internal Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-BiomX Announces Discontinuation Of Phase 2b Bx004 Trial Following Internal Review</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Biomx Inc <span>PHGE.A</span>:</p><ul><li><p>BIOMX ANNOUNCES DISCONTINUATION OF PHASE 2B BX004 TRIAL FOLLOWING INTERNAL REVIEW</p></li><li><p>BIOMX INC - PLANS COST-CUTTING MEASURES INCLUDING WORKFORCE REDUCTION</p></li><li><p>BIOMX INC - DECISION FOLLOWS SAFETY REVIEW BY INDEPENDENT DMC</p></li><li><p>BIOMX INC - SEES POTENTIAL IN BX011 FOR S. AUREUS INFECTIONS</p></li></ul><p>Source text: <span>ID:nGNX8KfLKK</span></p><p>Further company coverage: <span>PHGE.A</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUAFLY3C:1","article_id":"2589358837","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589358837","pubTimestamp":1765197263,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-BiomX Announces Discontinuation Of Phase 2b Bx004 Trial Following Internal ReviewDec 8 (Reuters) - Biomx Inc PHGE.A:BIOMX ANNOUNCES DISCONTINUATION OF PHASE 2B BX004 TRIAL FOLLOWING INTERNAL REV","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PHGE":"BiomX Inc."},"translate_title":"简报-BiomX宣布在内部审查后停止2b期Bx004试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHGE":0.9},"content_text":"BRIEF-BiomX Announces Discontinuation Of Phase 2b Bx004 Trial Following Internal ReviewDec 8 (Reuters) - Biomx Inc PHGE.A:BIOMX ANNOUNCES DISCONTINUATION OF PHASE 2B BX004 TRIAL FOLLOWING INTERNAL REVIEWBIOMX INC - PLANS COST-CUTTING MEASURES INCLUDING WORKFORCE REDUCTIONBIOMX INC - DECISION FOLLOWS SAFETY REVIEW BY INDEPENDENT DMCBIOMX INC - SEES POTENTIAL IN BX011 FOR S. AUREUS INFECTIONSSource text: ID:nGNX8KfLKKFurther company coverage: PHGE.A ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589358837","isCrawlerRequest":true}